Class: Centrally Acting Skeletal Muscle Relaxant
Dosage Forms. Tablet: 250 mg, 350 mg
Common FDA Label Indication, Dosing, and Titration.
1. Disorder of musculoskeletal system: 250-350 mg po tid and hs
Off-Label Uses. None
MOA. Carisoprodol blocks interneuronal activity in descending reticular formation and spinal cord, resulting in muscle relaxation.
Drug Characteristics: Carisoprodol
Medication Safety Issues: Carisoprodol
Drug Interactions: Carisoprodol
Adverse Reactions: Carisoprodol
Efficacy Monitoring Parameters. Reduction in pain and muscle spasms.
Toxicity Monitoring Parameters. Seek medical attention if idiosyncratic symptoms such as extreme weakness, transient quadriplegia, dizziness, confusion occur within minutes or hours after first dose.
Key Patient Counseling Points. Patients should avoid activities requiring mental alertness or coordination until drug effects are known, as drug may cause dizziness or sedative effects. Patients withdrawing from prolonged therapy should be monitored carefully for withdrawal symptoms, including seizures.
Clinical Pearls. Carisoprodol is used for the relief of discomfort associated with acute, painful musculoskeletal conditions in adults and should be used for only short periods (up to 2 or 3 wk). The drug was approved by the FDA in 1959 and limited pharmacologic and pharmacokinetic data are available.